The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...

Scientists at UMass Amherst and Ernest Pharmaceuticals developed BacID, a bacterial cancer therapy activated by aspirin. This ...

Expected to begin in 2027, the trials will involve human patients, and the researchers are working to obtain the necessary ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.

New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...

Since the exact cause is not known, it may not be easy to prevent breast cancer. However, reducing the risks of breast cancer ...